CN116287252A - 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 - Google Patents
长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 Download PDFInfo
- Publication number
- CN116287252A CN116287252A CN202310131492.7A CN202310131492A CN116287252A CN 116287252 A CN116287252 A CN 116287252A CN 202310131492 A CN202310131492 A CN 202310131492A CN 116287252 A CN116287252 A CN 116287252A
- Authority
- CN
- China
- Prior art keywords
- apcdd1l
- pancreatic cancer
- sample
- prognosis
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 57
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 57
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 57
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 57
- 238000001514 detection method Methods 0.000 title claims abstract description 18
- 108091027963 non-coding RNA Proteins 0.000 title claims abstract description 12
- 102000042567 non-coding RNA Human genes 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 238000004393 prognosis Methods 0.000 claims abstract description 27
- 238000003745 diagnosis Methods 0.000 claims abstract description 24
- 238000011156 evaluation Methods 0.000 claims abstract description 15
- 239000002773 nucleotide Substances 0.000 claims abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 8
- 239000000523 sample Substances 0.000 claims description 34
- 238000004458 analytical method Methods 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 5
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000002327 eosinophilic effect Effects 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 210000002503 granulosa cell Anatomy 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 3
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000000649 small cell carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 5
- 238000013399 early diagnosis Methods 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 101150040301 APCDD1L gene Proteins 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Databases & Information Systems (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
组分 | 含量 |
qPCR扩增Mix | 10μL |
cDNA | 2μL |
PCR上游引物 | 0.8μL |
PCR下游引物 | 0.8μL |
ddH2O | 6.4μL |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310131492.7A CN116287252B (zh) | 2023-02-17 | 2023-02-17 | 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310131492.7A CN116287252B (zh) | 2023-02-17 | 2023-02-17 | 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116287252A true CN116287252A (zh) | 2023-06-23 |
CN116287252B CN116287252B (zh) | 2024-03-08 |
Family
ID=86812330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310131492.7A Active CN116287252B (zh) | 2023-02-17 | 2023-02-17 | 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116287252B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109371133A (zh) * | 2018-12-03 | 2019-02-22 | 江苏大学附属医院 | 一组与胰腺癌相关的LncRNA分子标记物及其应用 |
CN109402254A (zh) * | 2018-09-04 | 2019-03-01 | 复旦大学附属华山医院 | 一种预测胰腺癌术后生存的LncRNA模型及检测试剂盒 |
CN112534067A (zh) * | 2018-06-22 | 2021-03-19 | 蓝星基因组股份有限公司 | 用于分配起源组织的无细胞核酸样品的羟甲基化分析及相关使用方法 |
JP2022187310A (ja) * | 2021-06-07 | 2022-12-19 | 国立大学法人山口大学 | 膵がん化学療法における副作用発生リスクの予測を補助する方法 |
-
2023
- 2023-02-17 CN CN202310131492.7A patent/CN116287252B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112534067A (zh) * | 2018-06-22 | 2021-03-19 | 蓝星基因组股份有限公司 | 用于分配起源组织的无细胞核酸样品的羟甲基化分析及相关使用方法 |
CN109402254A (zh) * | 2018-09-04 | 2019-03-01 | 复旦大学附属华山医院 | 一种预测胰腺癌术后生存的LncRNA模型及检测试剂盒 |
CN109371133A (zh) * | 2018-12-03 | 2019-02-22 | 江苏大学附属医院 | 一组与胰腺癌相关的LncRNA分子标记物及其应用 |
JP2022187310A (ja) * | 2021-06-07 | 2022-12-19 | 国立大学法人山口大学 | 膵がん化学療法における副作用発生リスクの予測を補助する方法 |
Non-Patent Citations (1)
Title |
---|
SHEN LI: "《BIOENGINEERED》", pages: 7188 - 7204 * |
Also Published As
Publication number | Publication date |
---|---|
CN116287252B (zh) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107435062B (zh) | 甄别肺部微小结节良恶性的外周血基因标志物及其用途 | |
CN113528672B (zh) | 用于膀胱癌早期筛查的引物和探针组合、试剂盒及应用 | |
CN108998531B (zh) | 肺癌下调长链非编码rna标志物及其应用 | |
CN111424085B (zh) | tRNA来源片段在制备乳腺癌诊断试剂中的应用 | |
CN111763740B (zh) | 基于lncRNA分子模型预测食管鳞癌患者新辅助放化疗的疗效和预后的系统 | |
TWI758670B (zh) | 健康風險評估方法 | |
CN108998530B (zh) | 肺癌上调长链非编码rna标志物及其应用 | |
CN116287252B (zh) | 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 | |
CN114107498B (zh) | 结直肠癌血液检测标记物及其应用 | |
CN116189904A (zh) | 一种分化型甲状腺癌的基因甲基化诊断模型及其构建方法 | |
WO2022170133A1 (en) | Micro rna liver cancer markers and uses thereof | |
CN114107514A (zh) | 一种用于结直肠癌诊断的miRNA分子标志物及其试剂盒 | |
CN114457160A (zh) | miRNA分子作为早期肺癌检测标志物的应用 | |
CN111172285A (zh) | 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用 | |
CN116219017B (zh) | 生物标志物在制备卵巢癌诊断和/或预后的产品中的应用 | |
CN115820858B (zh) | 一种血清在制备云南宣威肺癌诊断药物中的应用 | |
CN113801936B (zh) | 用于肺癌诊断的试剂盒、装置及方法 | |
US11807908B2 (en) | Genetic markers used for identifying benign and malignant pulmonary micro-nodules and the application thereof | |
CN109182520B (zh) | 一种宫颈癌及其癌前病变检测试剂盒及其应用 | |
CN112725452A (zh) | Cdkl1基因或蛋白作为黑色素瘤诊断标志物的用途 | |
CN112680525A (zh) | Ca8基因或蛋白作为黑色素瘤诊断标志物的用途 | |
CN113832142A (zh) | 粪便人类基因组dna提取方法及应用 | |
JP2024043823A (ja) | 対象のがん罹患の可能性を分析する方法 | |
CN117660653A (zh) | 一种用于早期肺癌诊断的血清miRNA标志物组合及试剂盒 | |
CN118652976A (zh) | 识别受试体的特征的方法及微rna癌标志物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240131 Address after: 200092 207A room, Tongji Science and Technology Park, 65 Chifeng Road, Shanghai, Yangpu District Applicant after: SHANGHAI TONEKER BIOTECHNOLOGY Co.,Ltd. Country or region after: China Address before: 237372 A7 building, Wutong Pioneer Park, modern industrial park, Jinzhai, Lu'an, Anhui Applicant before: ANHUI TONGKE BIOTECHNOLOGY Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of long chain non coding RNA APCDD1L-DT in preparation of products for detection of pancreatic cancer Granted publication date: 20240308 Pledgee: Bank of Shanghai Co.,Ltd. Puxi Sub branch Pledgor: SHANGHAI TONEKER BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980025658 |